Breast Imaging

How Should You Image the Axilla After Neoadjuvant Therapy if It Was Never Previously Assessed?

·
How Should You Image the Axilla After Neoadjuvant Therapy if It Was Never Previously Assessed?

A 52-year-old male patient with hormone receptor-positive breast cancer has successfully completed his course of neoadjuvant chemotherapy. His primary breast tumor shows an excellent clinical response. At his initial diagnosis, he was considered clinically node-negative based on physical exam, but his axilla was never evaluated with imaging. Now, as you plan his definitive surgery, the surgical oncologist asks for a formal assessment of his axillary lymph node status to determine the appropriate surgical approach—sentinel lymph node biopsy versus a more extensive axillary dissection. The critical question is which imaging study to order first to evaluate the axilla in this specific post-treatment, pre-operative context.

According to the American College of Radiology (ACR) Appropriateness Criteria, the initial imaging study for this exact situation is US axilla, which is rated Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies to a very specific patient population: adults of any gender identity (female, male, transfeminine, or transmasculine) with a known diagnosis of breast cancer who have completed neoadjuvant systemic therapy. The key distinguishing factors for this workflow are twofold: the patient was clinically node-negative by physical exam before starting therapy, and, crucially, the axilla was not evaluated with imaging (like ultrasound) or biopsy prior to or during the neoadjuvant course.

This scenario must be distinguished from several similar, but distinct, clinical situations that follow different diagnostic pathways:

  • Known Node-Positive Disease Pre-Therapy: If a patient had a biopsy-proven positive axillary lymph node before neoadjuvant chemotherapy, the imaging goal is different. The focus becomes assessing response in that known metastatic node, often involving targeted axillary dissection, which is a separate ACR variant.
  • Axilla Imaged Before Therapy: If an axillary ultrasound was performed before neoadjuvant therapy and was negative, post-therapy imaging is still performed, but the pre-treatment imaging serves as a valuable baseline for comparison. This article specifically addresses the scenario where no such baseline exists.
  • Initial Staging of Breast Cancer: This workflow is not for the initial workup of a newly diagnosed breast cancer patient before any treatment has begun. It is exclusively for the post-neoadjuvant, pre-surgical setting.

What Diagnoses Are You Working Up in This Scenario?

The primary goal of imaging in this context is to determine the pathologic status of the axillary lymph nodes after systemic therapy, which directly influences the surgical plan. The differential considerations are focused on the state of the nodes.

Residual Axillary Nodal Disease
This is the most critical finding to identify. Despite a good response in the primary breast tumor, metastatic cancer cells can persist in the lymph nodes. Identifying suspicious nodes allows for pre-operative biopsy. If positive, this finding may change the planned surgery from a sentinel lymph node biopsy (SLNB) to a more comprehensive axillary lymph node dissection (ALND), potentially sparing the patient a second operation.

Pathologic Complete Response (pCR) in the Axilla
This is the ideal outcome, where neoadjuvant therapy has eradicated all cancer from the lymph nodes. Imaging that shows no suspicious nodes supports this possibility and reinforces the plan for a less invasive SLNB at the time of surgery to confirm the pCR.

Benign Reactive Lymphadenopathy
Neoadjuvant chemotherapy, as well as the body’s response to the tumor, can cause lymph nodes to become enlarged and inflamed for benign reasons. These reactive nodes can sometimes mimic malignancy on imaging. A key role of high-resolution imaging is to differentiate features of reactive change (e.g., preserved fatty hilum, uniform cortical thickening) from features of malignancy.

Normal Axillary Lymph Nodes
In some cases, the lymph nodes may appear entirely normal, with no signs of either metastatic involvement or significant reactive changes. This finding strongly supports proceeding with SLNB.

Why Is Axillary Ultrasound the Recommended Initial Study?

For a patient who has completed neoadjuvant chemotherapy and requires a first-time evaluation of a clinically negative axilla, the ACR designates US axilla as Usually Appropriate. This recommendation is based on the modality’s high spatial resolution, lack of ionizing radiation, and ability to guide immediate biopsy if needed.

The rationale for this choice is multifaceted:

  • Superior Morphologic Detail: Axillary ultrasound provides excellent visualization of lymph node architecture. It can accurately assess key features suspicious for malignancy, such as cortical thickening (especially eccentric), rounding of the node, and obliteration of the normal fatty hilum. This level of detail is crucial for distinguishing residual disease from benign post-treatment changes.
  • Guidance for Biopsy: If a suspicious node is identified, ultrasound is the ideal modality to guide a fine-needle aspiration (FNA) or core needle biopsy in the same session. This provides a definitive pathologic diagnosis before surgery, directly impacting the surgical plan.
  • Safety and Accessibility: Ultrasound uses no ionizing radiation (0 mSv) and does not require intravenous contrast, avoiding potential risks of allergic reaction or nephrotoxicity. It is also widely available and less costly than other cross-sectional imaging modalities.

In contrast, other imaging studies are considered Usually not appropriate for this specific initial evaluation:

  • MRI breast without and with IV contrast: While breast MRI is excellent for evaluating response in the primary tumor, its utility for a dedicated axillary evaluation is less established than targeted ultrasound. It can be susceptible to false positives from post-chemotherapy inflammation and has lower spatial resolution for subtle nodal features compared to a high-frequency ultrasound transducer.
  • FDG-PET/CT skull base to mid-thigh: This modality is a powerful tool for detecting distant metastatic disease but is not the recommended first step for a focused axillary assessment. It involves a significant radiation dose (☢☢☢☢ 10-30 mSv) and can show false-positive uptake in inflamed but benign lymph nodes, leading to unnecessary follow-up procedures. Its role is in systemic staging, not the detailed nodal morphologic assessment required here.

What’s Next After Axillary Ultrasound? Downstream Workflow

The results of the axillary ultrasound create a clear decision tree for the surgeon and oncologist, guiding the next steps in management.

  • If the Ultrasound is Negative: If the ultrasound shows only normal-appearing or clearly benign lymph nodes, the patient typically proceeds to surgery with a planned sentinel lymph node biopsy (SLNB). The SLNB procedure will then provide the definitive pathologic assessment of the nodal basin.
  • If the Ultrasound is Positive (Suspicious Node Identified): When one or more lymph nodes display suspicious features (e.g., thickened cortex >3 mm, loss of fatty hilum), the immediate next step is an ultrasound-guided biopsy of the most abnormal-appearing node.
  • If Biopsy is Positive for Malignancy: This confirms residual nodal disease. The patient may be a candidate for axillary lymph node dissection (ALND) or, in some centers, a targeted axillary dissection (TAD), where the clipped node (if one was placed) and sentinel nodes are removed. This pre-operative confirmation helps avoid a two-step surgical process.
  • If Biopsy is Negative for Malignancy: This result can represent a false negative or a complete response in a previously involved node. In this case, the patient usually still proceeds to SLNB or TAD to ensure the nodal basin is accurately staged.
  • If the Ultrasound is Indeterminate: In cases where a node is mildly abnormal but does not meet definitive criteria for suspicion, management may involve a multidisciplinary discussion. Depending on the level of concern, options include proceeding with biopsy for a definitive answer or moving forward with SLNB, acknowledging the slightly higher pre-test probability of nodal involvement.

Pitfalls to Avoid (and When to Get Help)

Navigating this specific clinical scenario requires attention to detail to avoid common errors that can impact patient care.

  • Pitfall: Mistaking Reactive Nodes for Malignancy. Post-chemotherapy inflammation is common. Rely on strict morphologic criteria for suspicion and have a low threshold for biopsy to confirm, rather than assuming a slightly enlarged node is malignant.
  • Pitfall: Incomplete Sonographic Evaluation. The sonographer must systematically evaluate all axillary levels (I and II). A cursory scan can miss isolated positive nodes located deep or high in the axilla.
  • Pitfall: Assuming a Negative Clinical Exam is Sufficient. A physical examination of the axilla has low sensitivity for detecting nodal metastases, especially after neoadjuvant therapy has reduced tumor volume. Imaging is mandatory for accurate pre-operative staging.
  • Pitfall: Not Biopsy-Proving Suspicious Findings. A suspicious finding on ultrasound is an indication for biopsy, not for proceeding directly to ALND. Pathologic confirmation is the standard of care before committing a patient to a more morbid axillary surgery.

If there is significant discordance between the imaging findings and the clinical picture, or if a suspicious node is in a location that is difficult to access for biopsy (e.g., adjacent to the axillary vein), escalation to a radiologist specializing in breast procedures or a multidisciplinary tumor board discussion is warranted.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to imaging after neoadjuvant therapy for breast cancer, please consult the parent topic article. Additional tools can help you apply these guidelines in your practice.

Frequently Asked Questions

Why not skip imaging and proceed directly to sentinel lymph node biopsy for all clinically node-negative patients?

Pre-operative axillary ultrasound can identify patients with residual nodal disease that may not be found by sentinel lymph node biopsy alone, which has a higher false-negative rate after neoadjuvant chemotherapy. Finding a positive node on ultrasound and confirming it with biopsy allows for a more accurate surgical plan, such as an axillary lymph node dissection, potentially avoiding the need for a second surgery if the sentinel node were falsely negative.

How does this workflow change for a transmasculine patient who has had prior chest reconstruction (‘top surgery’)?

The imaging modality of choice remains axillary ultrasound. However, the surgical changes to the chest wall and axillary anatomy can make the examination more challenging. It is essential that the study be performed by an experienced sonographer who is aware of the patient’s surgical history to correctly identify anatomical landmarks and ensure a thorough evaluation of the axillary basin.

If a patient gets a breast MRI to assess primary tumor response, does that replace the need for a dedicated axillary ultrasound?

No. While a breast MRI protocol includes the axilla, a dedicated, high-resolution axillary ultrasound is considered superior for detailed morphologic evaluation of individual lymph nodes. The ACR specifically recommends targeted ultrasound for this question, as it provides the best detail and allows for immediate biopsy guidance if a suspicious node is found.

What is the key difference between this scenario and one where the axilla was evaluated *before* neoadjuvant chemotherapy?

If the axilla was evaluated before chemotherapy, a baseline is established. If a node was found to be positive and a clip was placed, the entire post-chemotherapy imaging and surgical approach is different, often focusing on targeted axillary dissection (TAD) to assess response in that specific, known-positive node. This scenario is for patients with no imaging baseline, making the post-chemotherapy ultrasound the first and most critical assessment.

Is an ultrasound-guided biopsy always required if a suspicious-looking node is found?

Yes, in virtually all cases. Surgical plans, especially those involving a more extensive procedure like an axillary lymph node dissection, should be based on pathologic proof of malignancy. An imaging finding of a ‘suspicious node’ is an indication for biopsy, not a definitive diagnosis. Biopsy confirmation is the standard of care before proceeding with more aggressive axillary surgery.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026